Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.6455 -0.0172 (-2.60%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	773,049
Open	0.6627
Bid (Size)	0.6450 (2,700)
Ask (Size)	0.6578 (2,300)
Prev. Close	0.6627
Today's Range	0.6400 - 0.6627
52wk Range	0.6230 - 5.140
Shares Outstanding	9,362,444
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

VISTAGEN CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Vistagen Therapeutics, Inc. Stockholders of the Upcoming Lead Plaintiff Deadline and Encourages Investors to Contact the Firm

Today 10:28 EST

From Bragar Eagel & Squire

Via GlobeNewswire

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit

Today 8:42 EST

From Faruqi & Faruqi LLP

Via GlobeNewswire

Performance

YTD	-4.9%	-4.9%
1 Month	-11.3%	-11.3%
3 Month	-84.1%	-84.1%
6 Month	-79.0%	-79.0%
1 Year	-78.3%	-78.3%

More News

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

January 23, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Why Did Vistagen Stock Tank 82% Today? ↗

December 17, 2025

Via Stocktwits

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

January 22, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN

January 20, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

VTGN Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action Lawsuit

January 20, 2026

From Robbins LLP

Via GlobeNewswire

VISTAGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. and Encourages Investors to Contact the Firm

January 20, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

January 16, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

January 16, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

January 16, 2026

From The Schall Law Firm

Via Business Wire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

January 16, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action

January 15, 2026

From Robbins LLP

Via Business Wire

These stocks have an unusual volume in today's session ↗

December 22, 2025

Via Chartmill

On Friday, there are stocks with unusual volume. Let's take a look. ↗

December 19, 2025

Via Chartmill

On Thursday, there are stocks with unusual volume. Let's take a look. ↗

December 18, 2025

Via Chartmill

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

December 17, 2025

From Vistagen

Via Business Wire

Vistagen Appoints Nick Tressler as Chief Financial Officer

December 01, 2025

From Vistagen

Via Business Wire

Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

November 26, 2025

From Vistagen

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 17, 2025

Via Benzinga

Vistagen (VTGN) Q2 2026 Earnings Call Transcript ↗

November 14, 2025

Via The Motley Fool

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

November 13, 2025

From Vistagen

Via Business Wire

Examining the Future: VistaGen Therapeutics's Earnings Outlook ↗

November 12, 2025

Via Benzinga

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

November 10, 2025

From Vistagen

Via Business Wire

Frequently Asked Questions

Is Vistagen Therapeutics, Inc. - Common Stock publicly traded?

Yes, Vistagen Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Vistagen Therapeutics, Inc. - Common Stock trade on?

Vistagen Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vistagen Therapeutics, Inc. - Common Stock?

The ticker symbol for Vistagen Therapeutics, Inc. - Common Stock is VTGN on the Nasdaq Stock Market

What is the current price of Vistagen Therapeutics, Inc. - Common Stock?

The current price of Vistagen Therapeutics, Inc. - Common Stock is 0.6455

When was Vistagen Therapeutics, Inc. - Common Stock last traded?

The last trade of Vistagen Therapeutics, Inc. - Common Stock was at 01/23/26 04:00 PM ET

What is the market capitalization of Vistagen Therapeutics, Inc. - Common Stock?

The market capitalization of Vistagen Therapeutics, Inc. - Common Stock is 6.04M

How many shares of Vistagen Therapeutics, Inc. - Common Stock are outstanding?

Vistagen Therapeutics, Inc. - Common Stock has 6M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.